Anonymous ID: 73b118 Sept. 1, 2023, 8:21 p.m. No.19475686   🗄️.is 🔗kun   >>5689 >>5709 >>5742 >>5752 >>5794 >>5795 >>5810 >>5842 >>6030 >>6261 >>6437 >>6456 >>6475

US Patent Law Can't Cope with Human Clones

If you can patent human cells, which you can under US law, then you could patent human organs. Somewhere after that the 13th Amendment kicks in.

 

IMMEDIATELY AFTER DR. Ian Wilmut, an embryologist at the Roslin Institute in Edinburgh, Scotland, announced last weekend that he and his research team had successfully cloned an adult sheep, people around the world began speculating on a matter closer to home: the cloning of humans.

 

Although Wilmut's experiments have focused on manufacturing animals for medical research, it's a sure bet that in the near future, someone somewhere will clone a human being. Although other countries, including England, have laws on the books banning human clones, the United States does not. In fact, US law actually encourages the patenting of life forms: The US Patent and Trademark Office has not only approved patents on human cells, cell lines, viruses, genes, animals, and numerous altered plants and microorganisms, but also awarded the National Institutes of Health a patent on the cell line of an indigenous Papua New Guinea man.

 

This patent first, ask questions later policy raises thorny legal and rights issues: Would human clones be patentable by the cloner, or would the clones retain intellectual property rights over their genetic material? Since they would be a product of replication rather than procreation, would they be considered humans, covered by all existing laws? And what about human-animal hybrids?

 

Dr. Lee Silver, a biologist at Princeton University, said that American law is not up to the task of deciding. "In the US, there are no federal laws on reproductive technologies, only state laws. If some states outlawed human cloning but others kept it legal, then anyone with the money could clone him or herself. And if every state banned human cloning, people would just go offshore to do it."

 

The Supreme Court faced life for the first time in 1980. The case was Diamond v. Chakrabarty, and the court, by the slimmest of majorities, ruled that an oil-munching microbe, indeed "anything under the sun that is made by man," could be patented. The US Patent Office applied this ruling to the patenting of plants in 1985, and two years later, expanded the statute to cover all animals, including human stem cells, cell lines, viruses, embryos, and fetuses.

 

Since the 13th Amendment to the Constitution prohibits slavery, the court found that human beings could not be patented. But the court did not address the most chilling question: How much of a person could you patent before the 13th Amendment kicks in?

 

"If you can patent human cells, which you can under US law, then could you patent human organs?" asks Joseph Mendelson, legal director for the International Center for Technology Assessment. "Right now, the answer would have to be yes. And if organs, why not a hand? Could you clone and patent a line of embryos predisposed to cancer or HIV for research?"

 

As the pace of scientific discovery outstrips the law's ability to cope, these are questions whose day has arrived. Since animals intermingled with human genes could be patented, would human-animal hybrids also be patentable? Could someone patent and enslave an entire race of human-animal hybrids not protected by the 13th Amendment? Is it possible a weapons contractor could count on patent protection to market an army of disposable human clones so long as the clones were genetically altered in some, perhaps tiny, way?

 

Unless American patent law is revised, the answer, says Mendelson, is yes. All the Patent Office requires for a successful application is for an "invention" to be novel, have utility, and not be a product of nature. Although DNA is obviously a product of nature, the law says it isn't after you isolate and clone it.

 

As for Dolly, the cloned sheep, it's not clear whether she could be patented in this country since she is identical to a preexisting sheep. Alter her genes in some small way, however, and she could be.

 

"US patent law is based on one size fits all," said Rebecca Eisenberg, a University of Michigan Law professor and expert on patent law. "In Europe, there is a tradition of asking moral and ethical questions about what can and should be patented. In the US, this is outside the concerns of the patent system, the mission of which is to promote technological progress. Any ban on life forms patents would have to come from Congress, and I don't see that happening since they are so pro-business."

 

https://www.wired.com/1997/02/us-patent-law-cant-cope-with-human-clones/

 

organ harvesting?…This stuff is just too scyfy…. can't believe im even looking into it.

Anonymous ID: 73b118 Sept. 1, 2023, 9:14 p.m. No.19475838   🗄️.is 🔗kun   >>5843 >>5862 >>6030 >>6261 >>6437 >>6452 >>6456 >>6475

What's up with the 110/maui, and https://www.icrc.org/en/document/somaliasomaliland-red-cross-visits-hundreds-detainees-las-anod

 

110 dead also.

Somalia/Somaliland: Red Cross visits hundreds of detainees in Las Anod

 

Nairobi (ICRC) – The International Committee of the Red Cross (ICRC) has carried out its first visit to over 300 detainees in Las Anod on Thursday, August 31. The detained combatants were captured in the latest round of fighting between the Somaliland army and SSC Khatumo forces that took place over the weekend.

NEWS RELEASE 01 SEPTEMBER 2023 SOMALIA

 

The ICRC visits detainees on both sides of the conflict, having previously visited Hargeisa Central Prison, where detainees from SSC Khatumo are held. The purpose of these visits is purely humanitarian, with the aim of ensuring that all detainees are treated humanely and that their families know their whereabouts.

 

“It is crucial that each detainee, from either side, is treated in accordance with international humanitarian law. This means that every detained person must have access to food and water and must never be subject to any form of ill-treatment,” said Pascal Cuttat, the head of the ICRC delegation in Somalia.

 

To help improve the material conditions of detention, ICRC teams also delivered blankets and mattresses to the places of detention in Las Anod.

 

Together with the Somali Red Crescent Society (SRCS), the ICRC also facilitated the transfer of four wounded prisoners to Qaran Hospital in Garowe, where they received specialized treatment.

 

Because of the fighting in and around Las Anod, many civilians lost contact with their family members. “Not knowing what happened to their loved ones is causing an incredible amount of anguish to people,” said Ahmed Said, who oversees ICRC’s operations in the northern part of the country. “Our offices in Hargeisa and Garowe, together with the SRCS, are trying to help people find their family members.”

 

Fighting between the Somaliland army and SSC Khatumo broke out early this year, forcing hundreds of thousands of people to flee their homes. Las Anod, the capital of Sool region, has been its main battleground, resulting in widespread destruction of civilian infrastructure.

 

The ICRC and the SRCS have supported hospitals in the area with medical supplies to help treat the wounded. At the same time, the SRCS ambulance response unit has carried out frontline triage, providing initial treatment, and then transporting wounded people for medical care. In the past week,110 wounded people were transported to hospital, while 42 dead bodies were collected to assist with the carrying out of dignified and proper burial.

Anonymous ID: 73b118 Sept. 1, 2023, 9:49 p.m. No.19475978   🗄️.is 🔗kun   >>5997

Was thinking earlier. If weather warfare is optional for the elite as in, hitting a city or say, islands… wouldn't it be like war. You know how war makes them moneh? well wouldn't they/them whoever in charge have unlimited access to moneh? just a thought.

Anonymous ID: 73b118 Sept. 1, 2023, 11:35 p.m. No.19476276   🗄️.is 🔗kun   >>6277 >>6437 >>6456 >>6475

Global Synthetic Biology: DNA Cloning Market Report (2022 to 2035) - by Type of Cloning Method, End-Users and Key Geographical RegionsJune 16, 2022 05:08 ET| Source: Research and MarketsDublin, June 16, 2022 (GLOBE NEWSWIRE) – The "Synthetic Biology: DNA Cloning Market by Type of Cloning Method, End-Users and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape and future potential of DNA cloning kits and reagents over the next decade. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.The field of gene cloning remained a largely unexplored area until 1973, when A. C. Y. Chang, H. W. Boyer, R. B. Helling and Stanley N. Cohen reported that individual genes can be cloned and isolated by cleaving DNA enzymatically into DNA fragments.Over time, the evolution of genome engineering techniques has allowed for alterations in the genome of microorganisms, thereby enabling the production of substances having various research and therapeutic applications. DNA cloning, which is a highly regulated method, is widely acknowledged and employed in many laboratories throughout the world.Specifically, during the COVID-19 pandemic, several well-known pharmaceutical and biopharmaceutical companies, as well as synthetic biology market players, have stepped forward and contributed to the research and development of a variety of products, such as test kits, treatment solutions, and vaccines to combat the coronavirus infection using synthetic biology.Based on the requirement, a variety of approaches, such as traditional cloning, PCR cloning, ligation independent cloning, seamless cloning and recombinational cloning, can be used to clone the DNA. Despite several advancements in the field of synthetic biology, the DNA cloning process is associated with various challenges, such as requirement of large amounts of expensive vectors for cloning, different reagents and longer time duration for the completion of process.In order to overcome these drawbacks, innovators in the pharmaceutical industry have undertaken several efforts for identifying and developing ways to improve the process of DNA cloning. Among other alternatives, the use of DNA cloning kits has emerged as a viable option for various drug developers and academic / research institutes to overcome the challenges associated with the traditional DNA cloning methods. Presently, more than 250 DNA cloning kits are available in the market.These cloning kits are affordable, easy to use and produce high quality results in short duration. Further, more than 3,200 patents and 4,000 research articles have been published for DNA cloning technologies in the past few years; this is indicative of the innovative efforts of the stakeholders engaged in this domain. Driven by the increasing demand for gene therapies and the introduction of novel and advanced DNA cloning technologies, the DNA cloning market is anticipated to witness steady growth in the coming years.In addition to other elements, the report includes:A detailed assessment of the current market landscape of DNA cloning kits, featuring information on the kit components (enzyme mix, vector, buffer, ligase and primer), number of reactions (between 1-35, between 36-50 and more than 50), type of cloning method used (ligation independent cloning, TA cloning, blunt cloning and in-fusion seamless cloning), type of fragment(s) cloned (multiple fragments, long fragments and short oligonucleotides), cloning time (5 minutes, between 10-30 minutes, between 31-60 minutes and more than 60 minutes), overlaps recognized, efficacy (80-100%, between >90->99%, >=98%) and kit shelf life (between 1-10 months, between 11-20 months, more than 20 months) and kit price (1-500 USD, 501-1500 USD, 1501-2500 USD, more than 2500 USD). In addition to this, the chapter features information on DNA cloning kit providers and a detailed analysis based on several relevant parameters, such as year of establishment, company size, region of headquarters, location of headquarters, company size and region of headquarters and leading players (in terms of number of products)

1/2

Anonymous ID: 73b118 Sept. 1, 2023, 11:36 p.m. No.19476277   🗄️.is 🔗kun   >>6437 >>6456 >>6475

>>19476276

.A detailed assessment of the current market landscape of DNA cloning regents, featuring information on reagent unit size (less than 500, 500-2,000 and more than 2,000), reagent concentration (less than 5 units/?l, 5-50 units/?l and more than 50 units/?l) reagent components (polymerase, buffers and additional components), exonuclease activity (5'->3' exonuclease activity and 3'-5' exonuclease activity), product overhangs (3'A, blunt, 3', 5', 3'/blunt, 3'A/ blunt, 3'-dA and 5'/3'), storage temperature (-20C,-30C to -10 C,-5 C to -30 C and -25 C to -15 C) and reagent price (less than USD 100, USD 100-500 and more than USD 500). In addition, the chapter features analysis related to DNA cloning reagents providers based on parameters, such as year of establishment, company size, region of headquarters, location of headquarters, company size and region of headquarters and leading players (in terms of number of products).Elaborate profiles of prominent players offering DNA cloning kits and reagents (shortlisted based on number of products), based in North America, Europe and Asia Pacific. Each profile features a brief overview of the company, details related to its financials (if available), DNA cloning kit portfolio, DNA cloning reagent portfolio, recent developments and an informed future outlook.An analysis of over 4,400 peer-reviewed scientific articles related to DNA cloning, published since 2018, based on several parameters, such as year of publication, type of article, type of publication, emerging focus areas, most popular publishers, most popular authors, and most popular journals.An analysis of more than 1,200 grants related to DNA cloning, since 2017, based on several parameters, such as year of grant, amount of grant, administrating institute center, support period, type of grant application, purpose of grant, activity code, study section awarded, emerging focus areas, most popular program officers, popular recipient organizations, popular recipient organizations and geographical distribution of recipient organizations.An in-depth analysis of over 3,400 patents that have been filed / granted for DNA cloning, between 2017-2021, based on multiple parameters, such as type of patent, publication year, application year, geography, CPC symbols, emerging focus areas, issuing authority involved, type of applicant, leading industry players, leading non-industry players, leading patent assignees, patent benchmarking analysis, patent characteristics and geography, patent age. It also includes a detailed patent valuation analysis and information on the leading patents.A case study on the DNA cloning service providers, featuring information and detailed analysis based on their year of establishment, company size, location of headquarters, region of headquarters and company size and region of headquarters.A case study on the general overview of advancements in DNA cloning, covering details related to the current and future trends in the domain.

https://www.globenewswire.com/en/news-release/2022/06/16/2463704/28124/en/Global-Synthetic-Biology-DNA-Cloning-Market-Report-2022-to-2035-by-Type-of-Cloning-Method-End-Users-and-Key-Geographical-Regions.html

Anonymous ID: 73b118 Sept. 1, 2023, 11:48 p.m. No.19476291   🗄️.is 🔗kun   >>6437 >>6456 >>6475

https://grants.nih.gov/grants/policy/cloning_directive.htm

 

Home » Policy & Compliance » Policy & Guidance » Presidential Directive: Prohibition on Federal Funding for Cloning of Human Beings - 3/4/1997

THE WHITE HOUSE

Office of the Press Secretary

 

 

For Immediate Release March 4, 1997

 

Memorandum for the Heads of Executive Departments and Agencies

 

SUBJECT: Prohibition on Federal Funding for Cloning of Human Beings

 

Recent accounts of advances in cloning technology, including the first successful cloning of an adult sheep, raise important questions. They potentially represent enormous scientific breakthroughs that could offer benefits in such areas as medicine and agriculture. But the new technology also raises profound ethical issues, particularly with respect to its possible use to clone humans. That is why last week I asked our National Bioethics Advisory Commission to thoroughly review the legal and ethical issues associated with the use of this technology and report back to me in 90 days.

 

Federal funds should not be used for cloning of human beings. The current restrictions on the use of Federal funds for research involving human embryos do not fully assure this result. In December 1994, I directed the National Institutes of Health not to fund the creation of human embryos for research purposes. The Congress extended this prohibition in FY 1996 and FY 1997 appropriations bills, barring the Department of Health and Human Services from supporting certain human embryo research. However, these restrictions do not explicitly cover human embryos created for implantation and do not cover all Federal agencies. I want to make it absolutely clear that no Federal funds will be used for human cloning. Therefore, I hereby direct that no Federal funds shall be allocated for cloning of human beings.

 

WILLIAM J. CLINTON